Drug Profile
DTP-poliovirus vaccine - KM Biologics
Alternative Names: Diphtheria tetanus pertussis and inactivated poliovirus vaccine - KM Biologics; QuattrovacLatest Information Update: 06 Nov 2020
Price :
$50
*
At a glance
- Originator Kaketsuken
- Developer KM Biologics
- Class Bacterial vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diphtheria; Pertussis; Poliomyelitis; Tetanus
Most Recent Events
- 01 Aug 2019 KM Biologics enters into a distribution agreement with Meiji Seika Pharma for its human vaccines portfolio (9307110; 9258921)
- 31 Jul 2019 Astellas Pharma and KM Biologics agreement for human vaccines expires (9307110; 9258921)
- 31 Oct 2012 Launched for Diphtheria in Japan (SC) - First global launch